New drug combo shows promise in shrinking lung tumors before surgery
NCT ID NCT05925530
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or chemoradiation can help people with stage IIB-IIIB non-small cell lung cancer. About 142 participants will receive the drug combination first, then either have surgery followed by more durvalumab, or undergo chemoradiation followed by durvalumab. The main goal is to see how many people can successfully have their tumors removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
The Bronx, New York, 10467, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Charlottesville, Virginia, 22908, United States
-
Research Site
Vienna, 1130, Austria
-
Research Site
Vienna, 1140, Austria
-
Research Site
Kingston, Ontario, K7L 2V7, Canada
-
Research Site
Chicoutimi, Quebec, G7H 5H6, Canada
-
Research Site
Montreal, Quebec, H4A 3J1, Canada
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Olomouc, 77900, Czechia
-
Research Site
Prague, 12808, Czechia
-
Research Site
Prague, 150 06, Czechia
-
Research Site
La Tronche, 38700, France
-
Research Site
Marseille, 13008, France
-
Research Site
Montpellier, 34295, France
-
Research Site
Mulhouse, 68070, France
-
Research Site
Paris, 75005, France
-
Research Site
Pessac, 33604, France
-
Research Site
Poitiers, 86000, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Berlin, 13125, Germany
-
Research Site
Cologne, 51109, Germany
-
Research Site
Großhansdorf, 22927, Germany
-
Research Site
Moers, 47441, Germany
-
Research Site
Würzburg, 97074, Germany
-
Research Site
Budapest, 1122, Hungary
-
Research Site
Törökbálint, 2045, Hungary
-
Research Site
Bari, 70124, Italy
-
Research Site
Bologna, 40138, Italy
-
Research Site
Milan, 20132, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Milan, 20141, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Palermo, 90127, Italy
-
Research Site
Pavia, 27100, Italy
-
Research Site
Peschiera del Garda, 37019, Italy
-
Research Site
Lisbon, 1350-352, Portugal
-
Research Site
Lisbon, 1500-650, Portugal
-
Research Site
Barakaldo, 48903, Spain
-
Research Site
Barcelona, 08025, Spain
-
Research Site
L'Hospitalet de Llobregat, 08908, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28046, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Valencia, 46009, Spain
-
Research Site
Zaragoza, 50009, Spain
-
Research Site
Solna, 171 64, Sweden
-
Research Site
Uppsala, SE-751 85, Sweden
Conditions
Explore the condition pages connected to this study.